HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era

Background. The outcome of HIV-associated non-Hodgkin lymphoma (NHL) has improved substantially in the highly active antiretroviral therapy (HAART) era. However, HIV-Burkitt lymphoma (BL), which accounts for up to 20% of HIV-NHL, has poor outcome with standard chemotherapy. Patients and Methods. We...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rodrigo, J. A., Hicks, L. K., Cheung, M. C., Song, K. W., Ezzat, H., Leger, C. S., Boro, J., Montaner, J. S. G., Harris, M., Leitch, H. A.
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi Publishing Corporation 2012
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3235428/
https://ncbi.nlm.nih.gov/pubmed/22190945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2012/735392
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados